These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 29950810)

  • 1. Linezolid: a review of its properties, function, and use in critical care.
    Hashemian SMR; Farhadi T; Ganjparvar M
    Drug Des Devel Ther; 2018; 12():1759-1767. PubMed ID: 29950810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linezolid Pharmacia Corp.
    Barrett JF
    Curr Opin Investig Drugs; 2000 Oct; 1(2):181-7. PubMed ID: 11249571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.
    Mendes RE; Deshpande LM; Jones RN
    Drug Resist Updat; 2014 Apr; 17(1-2):1-12. PubMed ID: 24880801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of linezolid combination therapy for serious infections: review of the current evidence.
    Chen H; Du Y; Xia Q; Li Y; Song S; Huang X
    Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1043-1052. PubMed ID: 31898798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid: an oxazolidinone antimicrobial agent.
    Fung HB; Kirschenbaum HL; Ojofeitimi BO
    Clin Ther; 2001 Mar; 23(3):356-91. PubMed ID: 11318073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linezolid: a review of its use in the management of serious gram-positive infections.
    Perry CM; Jarvis B
    Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid in children: recent patents and advances.
    Velissariou IM
    Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):73-7. PubMed ID: 18221164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
    Flamm RK; Mendes RE; Hogan PA; Streit JM; Ross JE; Jones RN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2273-80. PubMed ID: 26833165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit.
    Smith RL; Evans HL; Chong TW; McElearney ST; Hedrick TL; Swenson BR; Scheld WM; Pruett TL; Sawyer RG
    Surg Infect (Larchmt); 2008 Aug; 9(4):423-31. PubMed ID: 18759679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid: a promising option in the treatment of Gram-positives.
    Zahedi Bialvaei A; Rahbar M; Yousefi M; Asgharzadeh M; Samadi Kafil H
    J Antimicrob Chemother; 2017 Feb; 72(2):354-364. PubMed ID: 27999068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel multiresistance cfr plasmids in linezolid-resistant methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium (VRE) from a hospital outbreak: co-location of cfr and optrA in VRE.
    Lazaris A; Coleman DC; Kearns AM; Pichon B; Kinnevey PM; Earls MR; Boyle B; O'Connell B; Brennan GI; Shore AC
    J Antimicrob Chemother; 2017 Dec; 72(12):3252-3257. PubMed ID: 28961986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Linezolid-resistant Enterococcus faecium: the first G2576T mutation in Turkey].
    Afşar I; Barış I; Sener AG; Köksal V; Demirci M
    Mikrobiyol Bul; 2012 Jul; 46(3):516-8. PubMed ID: 22951666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of the classical G2576U mutation in linezolid resistant Staphylococcus aureus along with isolation of linezolid resistant Enterococcus faecium from a patient on short-term linezolid therapy: first report from India.
    Rai S; Niranjan DK; Kaur T; Singh NP; Hada V; Kaur IR
    Indian J Med Microbiol; 2015; 33(1):21-4. PubMed ID: 25559997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid: pharmacokinetic characteristics and clinical studies.
    Bouza E; Muñoz P
    Clin Microbiol Infect; 2001; 7 Suppl 4():75-82. PubMed ID: 11688537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid for the treatment of resistant gram-positive cocci.
    Bain KT; Wittbrodt ET
    Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissemination of cfr-mediated linezolid resistance among Staphylococcus species isolated from a teaching hospital in Beijing, China.
    Jian J; Chen L; Xie Z; Zhang M
    J Int Med Res; 2018 Sep; 46(9):3884-3889. PubMed ID: 29962305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.